Orthopaedic Professorship of the University Hospital Jena, Campus Eisenberg, Klosterlausnitzer Straße 81, 07607, Eisenberg, Germany.
Institute for Infectious Diseases and Infection Control, Jena University Hospital, 07747, Jena, Germany.
Sci Rep. 2021 Dec 6;11(1):23425. doi: 10.1038/s41598-021-02709-x.
Dalbavancin is a novel glycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). It is characterized by a potent activity against numerous Gram-positive pathogens, a long elimination half-life and a favorable safety profile. Most recently, its application for the treatment of periprosthetic joint infections (PJIs) was introduced. The aim of this study was to proof our hypothesis, that dalbavancin shows superior efficacy against staphylococcal biofilms on polyethylene (PE) disk devices compared with vancomycin and additive behavior in combination with rifampicin. Staphylococcus aureus biofilms were formed on PE disk devices for 96 h and subsequently treated with dalbavancin, vancomycin, rifampicin and dalbavancin-rifampicin combination at different concentrations. Quantification of antibacterial activity was determined by counting colony forming units (CFU/ml) after sonification of the PE, serial dilution of the bacterial suspension and plating on agar-plates. Biofilms were additionally life/dead-stained and visualized using fluorescence microscopy. Dalbavancin presented superior anti-biofilm activity compared to vancomycin. Additive effects of the combination dalbavancin and rifampicin were registered. Dalbavancin combined with rifampicin presents promising anti-biofilm activity characteristics in vitro. Further in vivo studies are necessary to establish recommendations for the general use of dalbavancin in the treatment of PJIs.
达巴万星是一种新型糖肽类抗生素，已被批准用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSIs）。它具有针对多种革兰氏阳性病原体的强大活性、较长的消除半衰期和良好的安全性特征。最近，其在治疗人工关节假体周围感染（PJIs）中的应用也得到了介绍。本研究的目的是验证我们的假设，即达巴万星在对抗聚乙烯（PE）盘设备上的葡萄球菌生物膜方面比万古霉素更有效，并与利福平联合具有增效作用。将金黄色葡萄球菌生物膜在 PE 盘设备上形成 96 小时，然后用不同浓度的达巴万星、万古霉素、利福平以及达巴万星-利福平联合进行处理。通过对 PE 进行超声处理、对细菌悬浮液进行连续稀释以及在琼脂平板上进行平板计数来确定抗菌活性的定量。生物膜还使用荧光显微镜进行死活染色和可视化。与万古霉素相比，达巴万星表现出优越的抗生物膜活性。达巴万星和利福平联合具有增效作用。达巴万星联合利福平在体外具有有前景的抗生物膜活性特征。需要进一步的体内研究来建立达巴万星在治疗 PJIs 中的一般用途的建议。
